---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-002577"
form_type: "8-K"
ticker: "CVM"
cik: "0000725363"
company_name: "CEL SCI CORP"
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T07:55:15.303280+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CEL-SCI Multikine Phase 3 shows 43% survival extension; BLA submission planned

## Summary
- Multikine extended overall survival by 43% (HR 0.70; 95% CI 0.49-1.00) vs SOC in 352 LR head & neck cancer patients.
- 5-year survival: 65.3% Multikine arm vs 49.7% control; benefit increased from 2.8% at 3yr to 15.6% at 5yr.
- 16.5% of Multikine patients had early tumor response (complete pathological) vs 0% control; responders' death rate 15.6% vs 48.7%.
- Data presented at ECHNO 2023; company plans to submit BLA to FDA for newly diagnosed locally advanced SCCHN.
- Intended patient population ~210,000 annual global cases; no new approved therapy for decades.

## SEC filing metadata
- accession: 0001654954-23-002577
- form_type: 8-K
- ticker: CVM
- cik: 0000725363
- company_name: CEL SCI CORP
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/725363/000165495423002577/0001654954-23-002577-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/725363/000165495423002577/cvm_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-002577
- JSON: https://secwatch.observer/filing/0001654954-23-002577.json
- Plain text: https://secwatch.observer/filing/0001654954-23-002577.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.